Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2025 R&D 100 Award Winners
    • 2025 Professional Award Winners
    • 2025 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Closing Arguments in Meningitis Outbreak Trial

By MaryBeth DiDonna | October 20, 2017

Lawyers in the trial of Glenn Chin, the supervisory pharmacist said to be involved in the 2012 meningitis outbreak that killed 64 people and sickened more than 700 others, have delivered their closing arguments as Chin faces possible conviction for second-degree murder as well as racketeering and mail fraud charges.

Read more: Cleanroom QC Agent: Pharmacist Told Me to “[Expletive] Off”: https://www.cemag.us/blog/2017/10/cleanroom-qc-agent-pharmacist-told-me-expletive

Chin’s trial comes six months after Barry J. Cadden, former co-owner and president of the New England Compounding Center in Framingham, Mass., was acquitted of murder in March 2017. Cadden was facing 25 counts of second-degree murder. The jury heard nine weeks of testimony and then deliberated for five days before presenting their verdict. Cadden was convicted of racketeering and fraud charges in June 2017, and was sentenced to nine years in prison. Chin has plead not guilty to his own charges.

A federal prosecutor in the Boston courthouse told jurors on Oct. 20 that Chin “acted with a depraved heart” as he knowingly producing non-sterile drugs.

“Make no mistake, Glenn Chin is not sitting in this court room because he was negligent or careless,” Assistant U.S. Attorney Amanda Strachan said. “He is here because of his deliberate choices.”

The prosecution has argued that Chin allowed his cleanroom workers to engage in lax cleanroom practices, such as forging cleaning logs, horseplay in the clean facility, and filling prescriptions under fake names such as “Mickey Mouse.”

Read more: Pharmacist’s Email: Cleanroom Practices “A Disaster Waiting to Happen”: https://www.cemag.us/blog/2017/10/pharmacists-email-cleanroom-practices-disaster-waiting-happen

Chin’s defense team has argued that Barry Cadden, currently serving his time in low-security federal penitentiary in Pennsylvania, is responsible for all of the corner-cutting that took place at the NECC, and Chin was merely following his boss’s orders.

Meanwhile, Strachan said, “There’s no such thing as a conspiracy of one. And the individuals who carry out crimes at their boss’s behest are just as guilty.”

The defense team did not call any witnesses as they rested their case. Instead they read from the transcript of the prosecution’s closing argument in Cadden’s trial, which stated that the compounding center was “Barry’s baby.”

The jury is expected to begin deliberations on Monday, Oct. 23.

Related Articles Read More >

6 essentials for seismic rated cleanrooms
Critical Spaces Control Platform
Phoenix Critical Spaces Control Platform uses automation to direct airflow
Endiatx
Endiatx aims to boldly go beyond traditional endoscopy and, eventually, redefine surgical scale
FMN Laboratory researcher in a cleanroom
Take our quiz to test your cleanroom IQ, covering everything from ISO Classes to ULPA filtration
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2025 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

R&D 100 Awards
Research & Development World
  • Subscribe to R&D World Magazine
  • Sign up for R&D World’s newsletter
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • 2025 R&D 100 Award Winners
    • 2025 Professional Award Winners
    • 2025 Special Recognition Winners
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
    • Content submission guidelines for R&D World
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE